Volatile organic compounds (VOCs) play a crucial role in affecting health, environmental integrity, and industrial operations, from air quality to medical diagnostics. The need for highly sensitive and selective detection of these compounds has spurred innovation in sensor technologies. This editorial introduces a special collection of articles in Applied Physics Reviews, exploring the latest advancements in VOC detection technologies. The featured works cover a range of innovations, including electrostatically formed nanowires, chiral liquid crystals, and graphene-based sensors enhanced by machine learning. Together, these articles highlight the dynamic progress in VOC detection, striving for improved sensitivity, selectivity, and real-world applicability. This special collection not only showcases pioneering research but also provides valuable insights into future trends and potential applications in the field.
Publications
Website LinkThis newsletter provides an update about the project activities.
This deliverable has been conceived in the frame of T4.2 “Clinical protocols and requirements”, which is devolted to the organization of the assessment methodology that will be implemented during the development of each use-case at different levels after risk stratification of citizens and clinical scenario. All the designs will be based on the feedback and results after of tasks developed in WP3 and WP5. The following actions will be deployed:
– developing and agreeing on the sampling plan;
– choosing and testing measurement instruments;
– choosing the early diagnosis clinical pathways;
– choosing the diagnosis workflow; and
– planning the data collection and the validation protocols.
After the protocol design (which has already been finalized), all the authorizations required by the regulatory authorities will be obtained.
This deliverable provides the essential regulatory and research documents for the beginning and development of Task 4.3: “General population screening” under which the prospective clinical study will start recruiting participants and gathering data for the LUCIA project.
The content of this deliverable summarizes the clinical protocol for the cohort study in the general population screening and the regulatory authorizations that must be obtained before the enrollment of the first participant in the study.
This deliverable includes the following information:
– Final version of the study protocols of each clinical site as sent to each one of their respective ethics committees.
– Regulatory authorizations required for the enrolment of the first study participant.
The consortium partners have finalized and agreed on the common prospective clinical protocol, which ensures we reach the highest standards of quality and clinical and scientific relevance. The protocols have already been submitted to each one of the Ethics Committees for its approval request in December 2023.
We foresee to obtain the approval of the Ethics Committees in the coming months and start the recruitment of the volunteers that will participate in the prospective clinical study as soon as we get those approvals.
Since the approval has not been obtained yet, we provide in this document the documents of Request for Evaluation of research projects by the Ethics Committees of each clinical site until we obtain the approvals. Once we get them, we will provide also these regulatory authorizations.
This deliverable has been conceived in the frame of T4.2 “Clinical protocols and requirements”, which is devolted to the organization of the assessment methodology that will be implemented during the development of each use-case at different levels after risk stratification of citizens and clinical scenario. All the designs will be based on the feedback and results after of tasks developed in WP3 and WP5. The following actions will be deployed:
– developing and agreeing on the sampling plan;
– choosing and testing measurement instruments;
– choosing the early diagnosis clinical pathways;
– choosing the diagnosis workflow; and
– planning the data collection and the validation protocols.
After the protocol design (which has already been finalized), all the authorizations required by the regulatory authorities will be obtained.
This deliverable provides the essential regulatory and research documents for the beginning and development of Task 4.3: “General population screening” under which the prospective clinical study will start recruiting participants and gathering data for the LUCIA project.
The content of this deliverable summarizes the clinical protocol for the cohort study in the general population screening and the regulatory authorizations that must be obtained before the enrollment of the first participant in the study.
This deliverable includes the following information:
– Final version of the study protocols of each clinical site as sent to each one of their respective ethics committees.
– Regulatory authorizations required for the enrolment of the first study participant.
The consortium partners have finalized and agreed on the common prospective clinical protocol, which ensures we reach the highest standards of quality and clinical and scientific relevance. The protocols have already been submitted to each one of the Ethics Committees for its approval request in December 2023.
We foresee to obtain the approval of the Ethics Committees in the coming months and start the recruitment of the volunteers that will participate in the prospective clinical study as soon as we get those approvals.
Since the approval has not been obtained yet, we provide in this document the documents of Request for Evaluation of research projects by the Ethics Committees of each clinical site until we obtain the approvals. Once we get them, we will provide also these regulatory authorizations.
